-
FLASH: a Fast joint model for Longitudinal And Survival data in High dimension
Authors:
Van Tuan Nguyen,
Adeline Fermanian,
Agathe Guilloux,
Antoine Barbieri,
Sarah Zohar,
Anne-Sophie Jannot,
Simon Bussy
Abstract:
This paper introduces a prognostic method called FLASH that addresses the problem of joint modelling of longitudinal data and censored durations when a large number of both longitudinal and time-independent features are available. In the literature, standard joint models are either of the shared random effect or joint latent class type. Combining ideas from both worlds and using appropriate regula…
▽ More
This paper introduces a prognostic method called FLASH that addresses the problem of joint modelling of longitudinal data and censored durations when a large number of both longitudinal and time-independent features are available. In the literature, standard joint models are either of the shared random effect or joint latent class type. Combining ideas from both worlds and using appropriate regularisation techniques, we define a new model with the ability to automatically identify significant prognostic longitudinal features in a high-dimensional context, which is of increasing importance in many areas such as personalised medicine or churn prediction. We develop an estimation methodology based on the EM algorithm and provide an efficient implementation. The statistical performance of the method is demonstrated both in extensive Monte Carlo simulation studies and on publicly available real-world datasets. Our method significantly outperforms the state-of-the-art joint models in predicting the latent class membership probability in terms of the C-index in a so-called ``real-time'' prediction setting, with a computational speed that is orders of magnitude faster than competing methods. In addition, our model automatically identifies significant features that are relevant from a practical perspective, making it interpretable.
△ Less
Submitted 7 September, 2023;
originally announced September 2023.
-
Bayesian Framework for Multi-Source Data Integration -- Application to Human Extrapolation From Preclinical Studies
Authors:
Sandrine Boulet,
Moreno Ursino,
Robin Michelet,
Linda B. S. Aulin,
Charlotte Kloft,
Emmanuelle Comets,
Sarah Zohar
Abstract:
In preclinical investigations, e.g. in in vitro, in vivo and in silico studies, the pharmacokinetic, pharmacodynamic and toxicological characteristics of a drug are evaluated before advancing to first-in-man trial. Usually, each study is analyzed independently and the human dose range does not leverage the knowledge gained from all studies. Taking into account the preclinical data through inferent…
▽ More
In preclinical investigations, e.g. in in vitro, in vivo and in silico studies, the pharmacokinetic, pharmacodynamic and toxicological characteristics of a drug are evaluated before advancing to first-in-man trial. Usually, each study is analyzed independently and the human dose range does not leverage the knowledge gained from all studies. Taking into account the preclinical data through inferential procedures can be particularly interesting to obtain a more precise and reliable starting dose and dose range. We propose a Bayesian framework for multi-source data integration from preclinical studies results extrapolated to human, which allow to predict the quantities of interest (e.g. the minimum effective dose, the maximum tolerated dose, etc.) in humans. We build an approach, divided in four main steps, based on a sequential parameter estimation for each study, extrapolation to human, commensurability checking between posterior distributions and final information merging to increase the precision of estimation. The new framework is evaluated via an extensive simulation study, based on a real-life example in oncology inspired from the preclinical development of galunisertib. Our approach allows to better use all the information compared to a standard framework, reducing uncertainty in the predictions and potentially leading to a more efficient dose selection.
△ Less
Submitted 1 December, 2022;
originally announced December 2022.
-
Co** with Information Loss and the Use of Auxiliary Sources of Data: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions
Authors:
Silvia Calderazzo,
Sergey Tarima,
Carissa Reid,
Nancy Flournoy,
Tim Friede,
Nancy Geller,
James L Rosenberger,
Nigel Stallard,
Moreno Ursino,
Marc Vandemeulebroecke,
Kelly Van Lancker,
Sarah Zohar
Abstract:
Clinical trials disruption has always represented a non negligible part of the ending of interventional studies. While the SARS-CoV-2 (COVID-19) pandemic has led to an impressive and unprecedented initiation of clinical research, it has also led to considerable disruption of clinical trials in other disease areas, with around 80% of non-COVID-19 trials stopped or interrupted during the pandemic. I…
▽ More
Clinical trials disruption has always represented a non negligible part of the ending of interventional studies. While the SARS-CoV-2 (COVID-19) pandemic has led to an impressive and unprecedented initiation of clinical research, it has also led to considerable disruption of clinical trials in other disease areas, with around 80% of non-COVID-19 trials stopped or interrupted during the pandemic. In many cases the disrupted trials will not have the planned statistical power necessary to yield interpretable results. This paper describes methods to compensate for the information loss arising from trial disruptions by incorporating additional information available from auxiliary data sources. The methods described include the use of auxiliary data on baseline and early outcome data available from the trial itself and frequentist and Bayesian approaches for the incorporation of information from external data sources. The methods are illustrated by application to the analysis of artificial data based on the Primary care pediatrics Learning Activity Nutrition (PLAN) study, a clinical trial assessing a diet and exercise intervention for overweight children, that was affected by the COVID-19 pandemic. We show how all of the methods proposed lead to an increase in precision relative to use of complete case data only.
△ Less
Submitted 22 June, 2022;
originally announced June 2022.
-
How to improve the quality of comparisons using external control cohorts in single-arm clinical trials?
Authors:
Jérôme Lambert,
Etienne Lengline,
Raphaël Porcher,
Rodolphe Thiébaut,
Sarah Zohar,
Sylvie Chevret
Abstract:
PURPOSE Providing rapid answers and early acces to patients to innovative treatments without randomized clinical trial (RCT) is growing, with benefit estimated from single-arm trials. This has become common in oncology, impacting the approval pathway of health technology assessment agencies. We aimed to provide some guidance for indirect comparison to external controls to improve the level of evid…
▽ More
PURPOSE Providing rapid answers and early acces to patients to innovative treatments without randomized clinical trial (RCT) is growing, with benefit estimated from single-arm trials. This has become common in oncology, impacting the approval pathway of health technology assessment agencies. We aimed to provide some guidance for indirect comparison to external controls to improve the level of evidence following such uncontrolled designs. METHODS We used the illustrative example of blinatumomab, a bispecific antibody for the treatment of B-cell ALL in complete remission (CR) with persistent minimal residual disease (MRD). Its approval relied on a single-arm trial conducted in 86 adults with B-cell ALL in CR, with undetectable MRD after one cycle as the main endpoint. To maximize the validity of indirect comparisons, a 3-step process for incorporating external control data to such single-arm trial data is proposed and detailed, with emphasis on the example. RESULTS The first step includes the definition of estimand, i.e. the treatment effect reflecting the clinical question. The second step relies on the adequate selection of external controls, from previous RCT or real-world data (RWD) obtained from patient cohort, registries, or electronic patient files. The third step consists in chosing the statistical approach targeting the treatment effect of interest, either in the whole population or restricted to the single-arm trial or the external controls, and depending on the available individual-level or aggregrated external data. CONCLUSION Validity of treatment effect derived from indirect comparisons heavily depends on carefull methodological considerations that are included in the proposed 3-step procedure. Because the level of evidence of a well conducted RCT cannot be guaranteed, post-market authorization evaluation is even more important than in standard settings.
△ Less
Submitted 20 June, 2022;
originally announced June 2022.
-
A straightforward meta-analysis approach for oncology phase I dose-finding studies
Authors:
Christian Röver,
Moreno Ursino,
Tim Friede,
Sarah Zohar
Abstract:
Phase I early-phase clinical studies aim at investigating the safety and the underlying dose-toxicity relationship of a drug or combination. While little may still be known about the compound's properties, it is crucial to consider quantitative information available from any studies that may have been conducted previously on the same drug. A meta-analytic approach has the advantages of being able…
▽ More
Phase I early-phase clinical studies aim at investigating the safety and the underlying dose-toxicity relationship of a drug or combination. While little may still be known about the compound's properties, it is crucial to consider quantitative information available from any studies that may have been conducted previously on the same drug. A meta-analytic approach has the advantages of being able to properly account for between-study heterogeneity, and it may be readily extended to prediction or shrinkage applications. Here we propose a simple and robust two-stage approach for the estimation of maximum tolerated dose(s) (MTDs) utilizing penalized logistic regression and Bayesian random-effects meta-analysis methodology. Implementation is facilitated using standard R packages. The properties of the proposed methods are investigated in Monte-Carlo simulations. The investigations are motivated and illustrated by two examples from oncology.
△ Less
Submitted 4 February, 2022; v1 submitted 12 October, 2021;
originally announced October 2021.
-
Probing the interplay between lattice dynamics and short-range magnetic correlations in CuGeO3 with femtosecond RIXS
Authors:
E. Paris,
C. W. Nicholson,
S. Johnston,
Y. Tseng,
M. Rumo,
G. Coslovich,
S. Zohar,
M. F. Lin,
V. N. Strocov,
R. Saint-Martin,
A. Revcolevschi,
A. Kemper,
W. Schlotter,
G. L. Dakovski,
C. Monney,
T. Schmitt
Abstract:
Investigations of magnetically ordered phases on the femtosecond timescale have provided significant insights into the influence of charge and lattice degrees of freedom on the magnetic sub-system. However, short-range magnetic correlations occurring in the absence of long-range order, for example in spin-frustrated systems, are inaccessible to many ultrafast techniques. Here, we show how time-res…
▽ More
Investigations of magnetically ordered phases on the femtosecond timescale have provided significant insights into the influence of charge and lattice degrees of freedom on the magnetic sub-system. However, short-range magnetic correlations occurring in the absence of long-range order, for example in spin-frustrated systems, are inaccessible to many ultrafast techniques. Here, we show how time-resolved resonant inelastic X-ray scattering (trRIXS) is capable of probing such short-ranged magnetic dynamics in a charge-transfer insulator through the detection of a Zhang-Rice singlet exciton. Utilizing trRIXS measurements at the O K-edge, and in combination with model calculations, we probe the short-range spin-correlations in the frustrated spin chain material CuGeO3 following photo-excitation, revealing a strong coupling between the local lattice and spin sub-systems.
△ Less
Submitted 8 April, 2021;
originally announced April 2021.
-
Bayesian dose-regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
Authors:
Emma Gerard,
Sarah Zohar,
Hoai-Thu Thai,
Christelle Lorenzato,
Marie-Karelle Riviere,
Moreno Ursino
Abstract:
Phase I dose-finding trials in oncology seek to find the maximum tolerated dose (MTD) of a drug under a specific schedule. Evaluating drug-schedules aims at improving treatment safety while maintaining efficacy. However, while we can reasonably assume that toxicity increases with the dose for cytotoxic drugs, the relationship between toxicity and multiple schedules remains elusive. We proposed a B…
▽ More
Phase I dose-finding trials in oncology seek to find the maximum tolerated dose (MTD) of a drug under a specific schedule. Evaluating drug-schedules aims at improving treatment safety while maintaining efficacy. However, while we can reasonably assume that toxicity increases with the dose for cytotoxic drugs, the relationship between toxicity and multiple schedules remains elusive. We proposed a Bayesian dose-regimen assessment method (DRtox) using pharmacokinetics/pharmacodynamics (PK/PD) information to estimate the maximum tolerated dose-regimen (MTD-regimen), at the end of the dose-escalation stage of a trial to be recommended for the next phase. We modeled the binary toxicity via a PD endpoint and estimated the dose-regimen toxicity relationship through the integration of a dose-regimen PD model and a PD toxicity model. For the dose-regimen PD model, we considered nonlinear mixed-effects models, and for the PD toxicity model, we proposed the following two Bayesian approaches: a logistic model and a hierarchical model. We evaluated the operating characteristics of the DRtox through simulation studies under various scenarios. The results showed that our method outperforms traditional model-based designs demonstrating a higher percentage of correctly selecting the MTD-regimen. Moreover, the inclusion of PK/PD information in the DRtox helped provide more precise estimates for the entire dose-regimen toxicity curve; therefore the DRtox may recommend alternative untested regimens for expansion cohorts. The DRtox should be applied at the end of the dose-escalation stage of an ongoing trial for patients with relapsed or refractory acute myeloid leukemia (NCT03594955) once all toxicity and PK/PD data are collected.
△ Less
Submitted 23 November, 2020;
originally announced November 2020.
-
Personalized Dynamic Treatment Regimes in Continuous Time: A Bayesian Approach for Optimizing Clinical Decisions with Timing
Authors:
William Hua,
Hongyuan Mei,
Sarah Zohar,
Magali Giral,
Yanxun Xu
Abstract:
Accurate models of clinical actions and their impacts on disease progression are critical for estimating personalized optimal dynamic treatment regimes (DTRs) in medical/health research, especially in managing chronic conditions. Traditional statistical methods for DTRs usually focus on estimating the optimal treatment or dosage at each given medical intervention, but overlook the important questi…
▽ More
Accurate models of clinical actions and their impacts on disease progression are critical for estimating personalized optimal dynamic treatment regimes (DTRs) in medical/health research, especially in managing chronic conditions. Traditional statistical methods for DTRs usually focus on estimating the optimal treatment or dosage at each given medical intervention, but overlook the important question of "when this intervention should happen." We fill this gap by develo** a two-step Bayesian approach to optimize clinical decisions with timing. In the first step, we build a generative model for a sequence of medical interventions-which are discrete events in continuous time-with a marked temporal point process (MTPP) where the mark is the assigned treatment or dosage. Then this clinical action model is embedded into a Bayesian joint framework where the other components model clinical observations including longitudinal medical measurements and time-to-event data conditional on treatment histories. In the second step, we propose a policy gradient method to learn the personalized optimal clinical decision that maximizes the patient survival by interacting the MTPP with the model on clinical observations while accounting for uncertainties in clinical observations learned from the posterior inference of the Bayesian joint model in the first step. A signature application of the proposed approach is to schedule follow-up visitations and assign a dosage at each visitation for patients after kidney transplantation. We evaluate our approach with comparison to alternative methods on both simulated and real-world datasets. In our experiments, the personalized decisions made by the proposed method are clinically useful: they are interpretable and successfully help improve patient survival.
△ Less
Submitted 18 February, 2021; v1 submitted 8 July, 2020;
originally announced July 2020.
-
Balanced Detection in Femtosecond X-ray Absorption Spectroscopy to Reach the Ultimate Sensitivity Limit
Authors:
W. F. Schlotter,
M. Beye,
S. Zohar,
G. Coslovich,
G. L. Dakovski,
M. -F. Lin,
Y. Liu,
A. Reid,
S. Stubbs,
P. Walter,
K. Nakahara,
P. Hart,
P. S. Miedema,
L. LeGuyader,
K. Hofhuis,
Phu Tran Phong Le,
Johan E. ten Elshof,
H. Hilgenkamp,
G. Koster,
X. H. Verbeek,
S. Smit,
M. S. Golden,
H. A. Durr,
A. Sakdinawat
Abstract:
X-ray absorption spectroscopy (XAS) is a powerful and well established technique with sensitivity to elemental and chemical composition. Despite these advantages, its implementation has not kept pace with the development of ultrafast pulsed x-ray sources where XAS can capture femtosecond chemical processes. X-ray Free Electron Lasers (XFELs) deliver femtosecond, narrow bandwidth (…
▽ More
X-ray absorption spectroscopy (XAS) is a powerful and well established technique with sensitivity to elemental and chemical composition. Despite these advantages, its implementation has not kept pace with the development of ultrafast pulsed x-ray sources where XAS can capture femtosecond chemical processes. X-ray Free Electron Lasers (XFELs) deliver femtosecond, narrow bandwidth ($\frac{ΔE}{E} < 0.5\%$) pulses containing $\sim 10^{10}$ photons. However, the energy contained in each pulse fluctuates thus complicating pulse by pulse efforts to quantify the number of photons. Improvements in counting the photons in each pulse have defined the state of the art for XAS sensitivity. Here we demonstrate a final step in these improvements through a balanced detection method that approaches the photon counting shot noise limit. In doing so, we obtain high quality absorption spectra from the insulator-metal transition in VO$_2$ and unlock a method to explore dilute systems, subtle processes and nonlinear phenomena with ultrafast x-rays. The method is especially beneficial for x-ray light sources where integration and averaging are not viable options to improve sensitivity.
△ Less
Submitted 24 June, 2020;
originally announced June 2020.
-
Using photoelectron spectroscopy to measure resonant inelastic X-ray scattering: A computational investigation
Authors:
Daniel J. Higley,
Hirohito Ogasawara,
Sioan Zohar,
Georgi L. Dakovski
Abstract:
Resonant inelastic X-ray scattering (RIXS) has become an important scientific tool. Nonetheless, conventional high-resolution RIXS measurements (<100 meV), especially in the soft x-ray range, require large and low-throughput grating spectrometers that limits measurement accuracy and simplicity. Here, we computationally investigate the performance of a different method for measuring RIXS, Photoelec…
▽ More
Resonant inelastic X-ray scattering (RIXS) has become an important scientific tool. Nonetheless, conventional high-resolution RIXS measurements (<100 meV), especially in the soft x-ray range, require large and low-throughput grating spectrometers that limits measurement accuracy and simplicity. Here, we computationally investigate the performance of a different method for measuring RIXS, Photoelectron Spectrometry for Analysis of X-rays (PAX). This method transforms the X-ray measurement problem of RIXS to an electron measurement problem, enabling use of compact, high-throughput electron spectrometers. In PAX, X-rays to be measured are incident on a converter material and the energy distribution of the resultant photoelectrons, the PAX spectrum, is measured with an electron spectrometer. The incident X-ray spectrum is then estimated through a deconvolution algorithm that leverages concepts from machine learning. We investigate a few example PAX cases. Using the 3d levels of Ag as a converter material, and with 10$^5$ detected electrons, we accurately estimate features with 100s of meV width in a model RIXS spectrum. Using a sharp Fermi edge to encode RIXS spectra, we accurately distinguish 100 meV FWHM peaks separated by 45 meV with 10$^7$ electrons detected that were photoemitted from within 0.4 eV of the Fermi level.
△ Less
Submitted 18 June, 2020;
originally announced June 2020.
-
Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?
Authors:
Cornelia Ursula Kunz,
Silke Jörgens,
Frank Bretz,
Nigel Stallard,
Kelly Van Lancker,
Dong Xi,
Sarah Zohar,
Christoph Gerlinger,
Tim Friede
Abstract:
Very recently the new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified and the coronavirus disease 2019 (COVID-19) declared a pandemic by the World Health Organization. The pandemic has a number of consequences for the ongoing clinical trials in non-COVID-19 conditions. Motivated by four currently ongoing clinical trials in a variety of disease areas we illustra…
▽ More
Very recently the new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified and the coronavirus disease 2019 (COVID-19) declared a pandemic by the World Health Organization. The pandemic has a number of consequences for the ongoing clinical trials in non-COVID-19 conditions. Motivated by four currently ongoing clinical trials in a variety of disease areas we illustrate the challenges faced by the pandemic and sketch out possible solutions including adaptive designs. Guidance is provided on (i) where blinded adaptations can help; (ii) how to achieve type I error rate control, if required; (iii) how to deal with potential treatment effect heterogeneity; (iv) how to utilize early readouts; and (v) how to utilize Bayesian techniques. In more detail approaches to resizing a trial affected by the pandemic are developed including considerations to stop a trial early, the use of group-sequential designs or sample size adjustment. All methods considered are implemented in a freely available R shiny app. Furthermore, regulatory and operational issues including the role of data monitoring committees are discussed.
△ Less
Submitted 28 May, 2020;
originally announced May 2020.
-
Efficient adaptive designs for clinical trials of interventions for COVID-19
Authors:
Nigel Stallard,
Lisa Hampson,
Norbert Benda,
Werner Brannath,
Tom Burnett,
Tim Friede,
Peter K. Kimani,
Franz Koenig,
Johannes Krisam,
Pavel Mozgunov,
Martin Posch,
James Wason,
Gernot Wassmer,
John Whitehead,
S. Faye Williamson,
Sarah Zohar,
Thomas Jaki
Abstract:
The COVID-19 pandemic has led to an unprecedented response in terms of clinical research activity. An important part of this research has been focused on randomized controlled clinical trials to evaluate potential therapies for COVID-19. The results from this research need to be obtained as rapidly as possible. This presents a number of challenges associated with considerable uncertainty over the…
▽ More
The COVID-19 pandemic has led to an unprecedented response in terms of clinical research activity. An important part of this research has been focused on randomized controlled clinical trials to evaluate potential therapies for COVID-19. The results from this research need to be obtained as rapidly as possible. This presents a number of challenges associated with considerable uncertainty over the natural history of the disease and the number and characteristics of patients affected, and the emergence of new potential therapies. These challenges make adaptive designs for clinical trials a particularly attractive option. Such designs allow a trial to be modified on the basis of interim analysis data or stopped as soon as sufficiently strong evidence has been observed to answer the research question, without compromising the trial's scientific validity or integrity. In this paper we describe some of the adaptive design approaches that are available and discuss particular issues and challenges associated with their use in the pandemic setting. Our discussion is illustrated by details of four ongoing COVID-19 trials that have used adaptive designs.
△ Less
Submitted 25 May, 2020;
originally announced May 2020.
-
Enhanced charge density wave coherence in a light-quenched, high-temperature superconductor
Authors:
S. Wandel,
F. Boschini,
E. H. da Silva Neto,
L. Shen,
M. X. Na,
S. Zohar,
Y. Wang,
S. B. Welch,
M. H. Seaberg,
J. D. Koralek,
G. L. Dakovski,
W. Hettel,
M-F. Lin,
S. P. Moeller,
W. F. Schlotter,
A. H. Reid,
M. P. Minitti,
T. Boyle,
F. He,
R. Sutarto,
R. Liang,
D. Bonn,
W. Hardy,
R. A. Kaindl,
D. G. Hawthorn
, et al. (6 additional authors not shown)
Abstract:
Superconductivity and charge density waves (CDW) are competitive, yet coexisting orders in cuprate superconductors. To understand their microscopic interdependence, a probe capable of discerning their interaction on its natural length and time scales is necessary. We use ultrafast resonant soft x-ray scattering to track the transient evolution of CDW correlations in YBa$_{2}$Cu$_{3}$O$_{6+x}$ foll…
▽ More
Superconductivity and charge density waves (CDW) are competitive, yet coexisting orders in cuprate superconductors. To understand their microscopic interdependence, a probe capable of discerning their interaction on its natural length and time scales is necessary. We use ultrafast resonant soft x-ray scattering to track the transient evolution of CDW correlations in YBa$_{2}$Cu$_{3}$O$_{6+x}$ following the quench of superconductivity by an infrared laser pulse. We observe a non-thermal response of the CDW order characterized by a near doubling of the correlation length within $\approx$ 1 picosecond of the superconducting quench. Our results are consistent with a model in which the interaction between superconductivity and CDW manifests inhomogeneously through disruption of spatial coherence, with superconductivity playing the dominant role in stabilizing CDW topological defects, such as discommensurations.
△ Less
Submitted 26 May, 2022; v1 submitted 9 March, 2020;
originally announced March 2020.
-
Preserving orbital order in a layered manganite by ultrafast hybridized band excitation
Authors:
L. Shen,
S. Mack,
G. Dakovski,
G. Coslovich,
O. Krupin,
M. Hoffmann,
S-W. Huang,
Y-D. Chuang,
J. A. Johnson,
S. Lieu,
S. Zohar,
C. Ford,
M. Kozina,
W. Schlotter,
M. P. Minitti,
J. Fujioka,
R. Moore,
W-S. Lee,
Z. Hussain,
Y. Tokura,
P. Littlewood,
J. J. Turner
Abstract:
In the mixed-valence manganites, a near-infrared laser typically melts the orbital and spin order simultaneously, corresponding to the photoinduced $d^{1}d^{0}$ $\xrightarrow{}$ $d^{0}d^{1}$ excitations in the Mott-Hubbard bands of manganese. Here, we use ultrafast methods -- both femtosecond resonant x-ray diffraction and optical reflectivity -- to demonstrate that the orbital response in the lay…
▽ More
In the mixed-valence manganites, a near-infrared laser typically melts the orbital and spin order simultaneously, corresponding to the photoinduced $d^{1}d^{0}$ $\xrightarrow{}$ $d^{0}d^{1}$ excitations in the Mott-Hubbard bands of manganese. Here, we use ultrafast methods -- both femtosecond resonant x-ray diffraction and optical reflectivity -- to demonstrate that the orbital response in the layered manganite Nd$_{1-x}$Sr$_{1+x}$MnO$_{4}$ ($\it{x}$ = 2/3) does not follow this scheme. At the photoexcitation saturation fluence, the orbital order is only diminished by a few percent in the transient state. Instead of the typical $d^{1}d^{0}$ $\xrightarrow{}$ $d^{0}d^{1}$ transition, a near-infrared pump in this compound promotes a fundamentally distinct mechanism of charge transfer, the $d^{0}$ $ \xrightarrow{}$ $d^{1}L$, where $\it{L}$ denotes a hole in the oxygen band. This novel finding may pave a new avenue for selectively manipulating specific types of order in complex materials of this class.
△ Less
Submitted 21 December, 2019;
originally announced December 2019.
-
Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors
Authors:
Moreno Ursino,
Christian Röver,
Sarah Zohar,
Tim Friede
Abstract:
Phase I dose-finding studies aim at identifying the maximal tolerated dose (MTD). It is not uncommon that several dose-finding studies are conducted, although often with some variation in the administration mode or dose panel. For instance, sorafenib (BAY 43-900) was used as monotherapy in at least 29 phase I trials according to a recent search in clinicaltrials.gov. Since the toxicity may not be…
▽ More
Phase I dose-finding studies aim at identifying the maximal tolerated dose (MTD). It is not uncommon that several dose-finding studies are conducted, although often with some variation in the administration mode or dose panel. For instance, sorafenib (BAY 43-900) was used as monotherapy in at least 29 phase I trials according to a recent search in clinicaltrials.gov. Since the toxicity may not be directly related to the specific indication, synthesizing the information from several studies might be worthwhile. However, this is rarely done in practice and only a fixed-effect meta-analysis framework was proposed to date. We developed a Bayesian random-effects meta-analysis methodology to pool several phase I trials and suggest the MTD. A curve free hierarchical model on the logistic scale with random effects, accounting for between-trial heterogeneity, is used to model the probability of toxicity across the investigated doses. An Ornstein-Uhlenbeck Gaussian process is adopted for the random effects structure. Prior distributions for the curve free model are based on a latent Gamma process. An extensive simulation study showed good performance of the proposed method also under model deviations. Sharing information between phase I studies can improve the precision of MTD selection, at least when the number of trials is reasonably large.
△ Less
Submitted 1 August, 2019;
originally announced August 2019.
-
Bi-cross validation for estimating spectral clustering hyper parameters
Authors:
Sioan Zohar,
Chun-Hong Yoon
Abstract:
One challenge impeding the analysis of terabyte scale x-ray scattering data from the Linac Coherent Light Source LCLS, is determining the number of clusters required for the execution of traditional clustering algorithms. Here we demonstrate that previous work using bi-cross validation (BCV) to determine the number of singular vectors directly maps to the spectral clustering problem of estimating…
▽ More
One challenge impeding the analysis of terabyte scale x-ray scattering data from the Linac Coherent Light Source LCLS, is determining the number of clusters required for the execution of traditional clustering algorithms. Here we demonstrate that previous work using bi-cross validation (BCV) to determine the number of singular vectors directly maps to the spectral clustering problem of estimating both the number of clusters and hyper parameter values. These results indicate that the process of estimating the number of clusters should not be divorced from the process of estimating other hyper parameters. Applying this method to LCLS x-ray scattering data enables the identification of dropped shots without manually setting boundaries on detector fluence and provides a path towards identifying rare and anomalous events.
△ Less
Submitted 17 September, 2019; v1 submitted 10 August, 2019;
originally announced August 2019.
-
Orbital dynamics during an ultrafast insulator to metal transition
Authors:
Sergii Parchenko,
Eugenio Paris,
Daniel McNally,
Elsa Abreu,
Marcus Dantz,
Elisabeth M. Bothschafter,
Alexander H. Reid,
William F. Schlotter,
Ming-Fu Lin,
Scott F. Wandel,
Giacomo Coslovich,
Sioan Zohar,
Georgi L. Dakovski,
Joshua. J. Turner,
Stefan Moeller,
Yi Tseng,
Milan Radovic,
Conny Saathe,
Marcus Agaaker,
Joseph E. Nordgren,
Steven L. Johnson,
Thorsten Schmitt,
Urs Staub
Abstract:
Phase transitions driven by ultrashort laser pulses have attracted interest both for understanding the fundamental physics of phase transitions and for potential new data storage or device applications. In many cases these transitions involve transient states that are different from those seen in equilibrium. To understand the microscopic properties of these states, it is useful to develop element…
▽ More
Phase transitions driven by ultrashort laser pulses have attracted interest both for understanding the fundamental physics of phase transitions and for potential new data storage or device applications. In many cases these transitions involve transient states that are different from those seen in equilibrium. To understand the microscopic properties of these states, it is useful to develop elementally selective probing techniques that operate in the time domain. Here we show fs-time-resolved measurements of V Ledge Resonant Inelastic X-Ray Scattering (RIXS) from the insulating phase of the Mott- Hubbard material V2O3 after ultrafast laser excitation. The probed orbital excitations within the d-shell of the V ion show a sub-ps time response, which evolve at later times to a state that appears electronically indistinguishable from the high-temperature metallic state. Our results demonstrate the potential for RIXS spectroscopy to study the ultrafast orbital dynamics in strongly correlated materials.
△ Less
Submitted 7 August, 2019;
originally announced August 2019.
-
Recent advances in methodology for clinical trials in small populations: the InSPiRe project
Authors:
T. Friede,
M. Posch,
S. Zohar,
C. Alberti,
N. Benda,
E. Comets,
S. Day,
A. Dmitrenko,
A. Graf,
B. K. Günhan,
S. W. Hee,
F. Lentz,
J. Madan,
F. Miller,
T. Ondra,
M. Pearce,
C. Röver,
A. Tournazi,
S. Unkel,
M. Ursino,
G. Wassmer,
N. Stallard
Abstract:
Where there are a limited number of patients, such as in a rare disease, clinical trials in these small populations present several challenges, including statistical issues. This led to an EU FP7 call for proposals in 2013. One of the three projects funded was the Innovative Methodology for Small Populations Research (InSPiRe) project. This paper summarizes the main results of the project, which w…
▽ More
Where there are a limited number of patients, such as in a rare disease, clinical trials in these small populations present several challenges, including statistical issues. This led to an EU FP7 call for proposals in 2013. One of the three projects funded was the Innovative Methodology for Small Populations Research (InSPiRe) project. This paper summarizes the main results of the project, which was completed in 2017. The InSPiRe project has led to development of novel statistical methodology for clinical trials in small populations in four areas. We have explored new decision-making methods for small population clinical trials using a Bayesian decision-theoretic framework to compare costs with potential benefits, developed approaches for targeted treatment trials, enabling simultaneous identification of subgroups and confirmation of treatment effect for these patients, worked on early phase clinical trial design and on extrapolation from adult to pediatric studies, develo** methods to enable use of pharmacokinetics and pharmacodynamics data, and also developed improved robust meta-analysis methods for a small number of trials to support the planning, analysis and interpretation of a trial as well as enabling extrapolation between patient groups. In addition to scientific publications, we have contributed to regulatory guidance and produced free software in order to facilitate implementation of the novel methods.
△ Less
Submitted 30 October, 2018;
originally announced November 2018.
-
Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions
Authors:
Steffen Unkel,
Christian Röver,
Nigel Stallard,
Norbert Benda,
Martin Posch,
Sarah Zohar,
Tim Friede
Abstract:
BACKGROUND: Randomized controlled trials (RCTs) are the gold standard design of clinical research to assess interventions. However, RCTs cannot always be applied for practical or ethical reasons. To investigate the current practices in rare diseases, we review evaluations of therapeutic interventions in paediatric multiple sclerosis (MS) and Creutzfeldt-Jakob disease (CJD). In particular, we shed…
▽ More
BACKGROUND: Randomized controlled trials (RCTs) are the gold standard design of clinical research to assess interventions. However, RCTs cannot always be applied for practical or ethical reasons. To investigate the current practices in rare diseases, we review evaluations of therapeutic interventions in paediatric multiple sclerosis (MS) and Creutzfeldt-Jakob disease (CJD). In particular, we shed light on the endpoints used, the study designs implemented and the statistical methodologies applied.
METHODS: We conducted literature searches to identify relevant primary studies. Data on study design, objectives, endpoints, patient characteristics, randomization and masking, type of intervention, control, withdrawals and statistical methodology were extracted from the selected studies. The risk of bias and the quality of the studies were assessed.
RESULTS: Twelve (seven) primary studies on paediatric MS (CJD) were included in the qualitative synthesis. No double-blind, randomized placebo-controlled trial for evaluating interventions in paediatric MS has been published yet. Evidence from one open-label RCT is available. The observational studies are before-after studies or controlled studies. Three of the seven selected studies on CJD are RCTs, of which two received the maximum mark on the Oxford Quality Scale. Four trials are controlled observational studies.
CONCLUSIONS: Evidence from double-blind RCTs on the efficacy of treatments appears to be variable between rare diseases. With regard to paediatric conditions it remains to be seen what impact regulators will have through e.g., paediatric investigation plans. Overall, there is space for improvement by using innovative trial designs and data analysis techniques.
△ Less
Submitted 21 February, 2016;
originally announced February 2016.
-
A compact apparatus for studies of element and phase-resolved ferromagnetic resonance
Authors:
D. A. Arena,
Y. Ding,
E. Vescovo,
S. Z. Zohar,
Y. Guan,
W. E. Bailey
Abstract:
We present a compact sample holder equipped with electromagnets and high frequency transmission lines; the sample holder is intended for combined x-ray magnetic circular dichroism (XMCD) and ferromagnetic resonance measurements (FMR). Time-resolved measurements of resonant x-ray detected FMR during forced precession are enabled by use of a rf excitation that is phase-locked to the storage ring b…
▽ More
We present a compact sample holder equipped with electromagnets and high frequency transmission lines; the sample holder is intended for combined x-ray magnetic circular dichroism (XMCD) and ferromagnetic resonance measurements (FMR). Time-resolved measurements of resonant x-ray detected FMR during forced precession are enabled by use of a rf excitation that is phase-locked to the storage ring bunch clock. Several applications of the combined XMCD + FMR technique are presented, demonstrating the flexibility of the experimental design.
△ Less
Submitted 14 May, 2009;
originally announced May 2009.
